- Home
- BEAM
as 07-01-2025 3:32pm EST
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.6B | IPO Year: | 2020 |
| Target Price: | $48.90 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.53 - $35.25 | Next Earning Date: | 08-05-2025 |
| Revenue: | $63,578,000 | Revenue Growth: | -82.38% |
| Revenue Growth (this year): | -16.21% | Revenue Growth (next year): | 8.82% |
Latest Beam Therapeutics Inc. News
BEAM Breaking Stock News: Dive into BEAM Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investor's Business Daily
11 days ago
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Investor's Business Daily
14 days ago
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
MT Newswires
19 days ago
Beam Therapeutics Reports Positive Update From Sickle Cell Disease Trial
GlobeNewswire
19 days ago
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
Zacks
a month ago
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?
Zacks
a month ago
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
MT Newswires
a month ago
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday
Compare BEAM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.